49 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
Rank Status Study
1 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
2 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
3 Recruiting Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Conditions: Ebola Virus Disease;   Hemorrhagic Fever
Interventions: Biological: VRC-EBOADC069-00-vp;   Biological: MVA-EbolaZ;   Other: Placebo
4 Recruiting STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: rVSVΔG-ZEBOV
5 Recruiting Diagnostic of Puumala Virus Infection in France
Conditions: Nephropathia Epidemica;   Hemorrhagic Fever With Renal Syndrome
Intervention:
6 Recruiting Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
Conditions: Viral Haemorrhagic Fever;   Dengue Fever
Interventions: Drug: Western Medicine;   Drug: TCM  and  Western Medicine
7 Recruiting Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: CYD Dengue and Japanese Encephalitis Vaccines;   Biological: Japanese Encephalitis and CYD Dengue Vaccines
8 Recruiting A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Condition: Ebola Virus Disease
Interventions: Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo
9 Not yet recruiting Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults
Condition: Prevention of Ebola Infection
Interventions: Biological: V920 Consistency Lot A;   Biological: V920 Consistency Lot B;   Biological: V920 Consistency Lot C;   Biological: V920 High-dose Lot;   Biological: Placebo to V920
10 Not yet recruiting A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV
Condition: Ebola Virus Disease
Interventions: Biological: ChAd3-EBO-Z;   Biological: Ad26.ZEBOV
11 Recruiting A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
Condition: Ebola Virus Disease
Interventions: Biological: MVA-EBO Z;   Biological: ChAd3-EBO Z
12 Not yet recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
13 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
14 Recruiting Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Condition: Ebola Virus
Interventions: Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Drug: Placebo
15 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
16 Recruiting Efficacy of Favipiravir Against Ebola (JIKI)
Condition: Ebola Virus Disease
Intervention: Drug: Favipiravir
17 Recruiting A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Conditions: Filovirus Infections;   Ebola Virus Infection
Interventions: Drug: BCX4430;   Drug: Placebo
18 Not yet recruiting Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)
Condition: Ebola Virus Disease
Interventions: Drug: Best Supportive Care;   Drug: Best Supportive Care + Amiodarone
19 Recruiting A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Condition: Acute Ebola Virus Disease
Intervention: Biological: INTERCEPT Plasma
20 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years